Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Background Immunotherapy with immune checkpoint inhibitors combined with an anti-angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus anti-angiogenic therapy alone in advanced solid tumours, but not in hepatocellular carcinoma. Therefore, a clinical study was conducted to compare the efficacy and safety of the anti-PD-1 antibody camrelizumab plus the VEGFR2-targeted TKI rivoceranib (also known as apatinib) versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.Methods This randomised, open-label, international phase 3 trial (CARES-310) was done at 95 study sites across 13 countries and regions worldwide. Patients with unresectable or metastatic hepatocellular carcinoma who had not previously received any systemic treatment were randomly assigned (1:1) to receive either camrelizumab 200 mg intravenously every 2 weeks plus rivoceranib 250 mg orally once daily or sorafenib 400 mg orally twice daily. Randomisation was done via a centralised interactive response system. The primary endpoints were progression-free survival, as assessed by the blinded independent review committee per Response Evaluation Criteria in Solid Tumours version 1.1, and overall survival in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of the study drugs. We report the findings from the prespecified primary analysis for progression-free survival and interim analysis for overall survival. This study is registered with ClinicalTrials.gov (NCT03764293).Findings Between June 28, 2019, and March 24, 2021, 543 patients were randomly assigned to the camrelizumab-rivoceranib (n=272) or sorafenib (n=271) group. At the primary analysis for progression-free survival (May 10, 2021), median follow-up was 7·8 months (IQR 4·1-10·6). Median progression-free survival was significantly improved with camrelizumab-rivoceranib versus sorafenib (5·6 months [95% CI 5·5-6·3] vs 3·7 months [2·8-3·7]; hazard ratio [HR] 0·52 [95% CI 0·41-0·65]; one-sided p<0·0001). At the interim analysis for overall survival (Feb 8, 2022), median follow-up was 14·5 months (IQR 9·1-18·7). Median overall survival was significantly extended with camrelizumab-rivoceranib versus sorafenib (22·1 months [95% CI 19·1-27·2] vs 15·2 months [13·0-18·5]; HR 0·62 [95% CI 0·49-0·80]; one-sided p<0·0001). The most common grade 3 or 4 treatment-related adverse events were hypertension (102 [38%] of 272 patients in the camrelizumab-rivoceranib group vs 40 [15%] of 269 patients in the sorafenib group), palmar-plantar erythrodysaesthesia syndrome (33 [12%] vs 41 [15%]), increased aspartate aminotransferase (45 [17%] vs 14 [5%]), and increased alanine aminotransferase (35 [13%] vs eight [3%]). Treatment-related serious adverse events were reported in 66 (24%) patients in the camrelizumab-rivoceranib group and 16 (6%) in the sorafenib group. Treatment-related death occurred in two patients: one patient in the camrelizumab-rivoceranib group (ie, multiple organ dysfunction syndrome) and one patient in the sorafenib group (ie, respiratory failure and circulatory collapse).Interpretation Camrelizumab plus rivoceranib showed a statistically significant and clinically meaningful benefit in progression-free survival and overall survival compared with sorafenib for patients with unresectable hepatocellular carcinoma, presenting as a new and effective first-line treatment option for this population.Funding Jiangsu Hengrui Pharmaceuticals and Elevar Therapeutics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Self-citationKudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Self-citationPembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Self-citationZhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Self-citationFinn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01307 · Cited by 1,789
Self-citationLenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Motzer, R., Alekseev, B., Rha, S.-Y., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., Kopyltsov, E., Méndez-Vidal, M. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035716 · Cited by 1,766
Cheng, A.-L., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V., Merle, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.030 · Cited by 1,743
Self-citation
Cited by
Singal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 951
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Llovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00469-2 · Cited by 469
Self-citationPrecision treatment in advanced hepatocellular carcinoma
Yang, X., Yang, C., Zhang, S., Geng, H., Zhu, A. X., Bernards, R., Qin, W., Fan, J., Wang, C., & Gao, Q. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.007 · Cited by 429
Self-citationHepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Metadata
- Authors
- Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., Hu, X., Meng, Z., Liang, J., Cheng, Y., Xiong, J., Ren, H., Yang, F., Li, W., Chen, Y., Zeng, Y., Sultanbaev, A., Pazgan-Simon, M., Pisetska, M., Melisi, D., Ponomarenko, D., Osypchuk, Y., Sinielnikov, I., Yang, T.-S., Liang, X., Chen, C., Wang, L., Cheng, A.-L., Kaseb, A., Vogel, A., Qin, S., Chan, S. L., Cheng, A.-L., Kaseb, A., Vogel, A., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., Hu, X., Meng, Z., Liang, J., Cheng, Y., Xiong, J., Ren, H., Yang, F., Li, W., Chen, Y., Zeng, Y., Sultanbaev, A., Pazgan-Simon, M., Pisetska, M., Melisi, D., Ponomarenko, D., Osypchuk, Y., Sinielnikov, I., Yang, T.-S., Liang, X., Chen, C., Wang, L., Zhang, M., Xu, L., Yuan, X., Li, D., Ying, J., Zhang, J., Zhang, T., Gu, K., He, Y., Hao, P., Jiang, D., Zhang, S., Xing, B., Zhang, B., Wang, D., Zhai, X., Liang, H., Cybulska-Stopa, B., Dvorkin, M., Stroyakovskiy, D., Nechaeva, M., Yen, C.-J., Su, W.-W., Chen, Y.-H., Bondarenko, I., Yang, L., Fang, W., Gomez-Martin, C., Ryu, M.-H., Kim, H.-S., Kim, J.-H., Zarubenkov, O., Orlova, R., Poddubskaya, E., Fadeeva, N., Makarova, Y., Chao, Y., Hung, C.-H., Neffa, M., Vynnychenko, O., Burgoyne, A., Hao, C., Mohr, R. U., Diaz-Beveridge, R., Feliu-Batlle, J., Cubillo-Gracian, A., Lee, A.-S., Daniele, B., Antonuzzo, L., Sangiovanni, A., Gasbarrini, A., Scartozzi, M., Ahn, M. S., Oh, S.-Y., Orlov, S., Harputluoglu, H., Oksuzoglu, B., Hsu, C., Rau, K.-M., Krechkovskyi, O., Yareshko, V., Xiong, H., Lee, F.-C., Jiang, Y., Gabayan, A., Crow, M., Van Steenkiste, C., & Verset, G.
- Affiliations
- National Taiwan University Hospital (TW)
- University of Verona (IT)
- Jilin Province Tumor Hospital (CN)
- Nanfang Hospital (CN)
- First Affiliated Hospital of Nanchang University (CN)
- Nanjing University of Chinese Medicine (CN)
- Jiangsu Hengrui Medicine (China) (CN)
- Sun Yat-sen University (CN)
- Chang Gung Memorial Hospital (TW)
- The Sixth People's Hospital of Shenyang (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- ORCID
- Zhang, Mingxiang
- Xu, Li
- Yuan, Xianglin
- Li, Da
- Zhang, Jingdong
- Zhang, Tao
- He, Yifu
- Jiang, Da
- Xing, Baocai
- Wang, Dong
- Liang, Houjie
- Stroyakovskiy, Daniil
- Nechaeva, Marina
- Yen, Chia-Jui
- Su, Wei-Wen
- Chen, Yen-Hao
- Bondarenko, Igor
- Yang, Lin
- Fang, Weijia
- Ryu, Min-Hee
- Poddubskaya, Elena
- Fadeeva, Natalia
- Chao, Yee
- Hung, Chao-Hung
- Burgoyne, Adam
- Mohr, Raphael U
- Daniele, Bruno
- Antonuzzo, Lorenzo
- Sangiovanni, Angelo
- Gasbarrini, Antonio
- Scartozzi, Mario
- Ahn, Mi Sun
- Hsu, Chiun
- Rau, Kun-Ming
- Lee, Fa-Chyi
- Jiang, Yixing
- Crow, Mary
- Verset, Gontran
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 402
- Issue
- 10408
- Pages
- 1133-1146
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4385211938
- Cited by
- 746
- References
- 46
- Citations by year
- 2026: 198 · 2025: 273 · 2024: 242 · 2023: 32
- FWCI
- 125.96
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-sa
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, cc-by-nc-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- camrelizumab, apatinib, sorafenib, hepatocellular carcinoma, unresectable liver cancer, first-line therapy, immune checkpoint inhibitors, anti-PD-1 therapy, VEGFR-2 inhibitors, progression-free survival, overall survival, treatment safety
- MeSH terms
- Sorafenib, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Pyridines, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. https://app.cochat.ai/papers/10.1016/s0140-6736(23)00961-3
- The paper
- Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., Hu, X., Meng, Z., Liang, J., Cheng, Y., Xiong, J., Ren, H., Yang, F., Li, W., Chen, Y., . . . Verset, G. (2023). Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. The Lancet. https://doi.org/10.1016/s0140-6736(23)00961-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.